IRIS
CONTE, BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.633
AS - Asia 1.112
EU - Europa 836
SA - Sud America 126
Continente sconosciuto - Info sul continente non disponibili 95
AF - Africa 94
OC - Oceania 2
Totale 3.898
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.547
SG - Singapore 462
RU - Federazione Russa 372
CN - Cina 180
HK - Hong Kong 179
IT - Italia 170
VN - Vietnam 104
BR - Brasile 88
ES - Italia 72
BD - Bangladesh 65
BJ - Benin 59
DE - Germania 59
CA - Canada 48
KR - Corea 40
FR - Francia 35
GB - Regno Unito 28
AT - Austria 22
IN - India 19
UA - Ucraina 18
ZA - Sudafrica 17
AR - Argentina 16
PL - Polonia 12
FI - Finlandia 10
JP - Giappone 9
IQ - Iraq 8
NL - Olanda 8
VE - Venezuela 7
MX - Messico 6
SE - Svezia 6
EC - Ecuador 5
IL - Israele 5
JM - Giamaica 5
TT - Trinidad e Tobago 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
CR - Costa Rica 4
EE - Estonia 4
ID - Indonesia 4
NI - Nicaragua 4
TN - Tunisia 4
CL - Cile 3
CW - ???statistics.table.value.countryCode.CW??? 3
GT - Guatemala 3
LB - Libano 3
PH - Filippine 3
PY - Paraguay 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TR - Turchia 3
AU - Australia 2
BE - Belgio 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
NP - Nepal 2
PK - Pakistan 2
PS - Palestinian Territory 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BS - Bahamas 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DK - Danimarca 1
EG - Egitto 1
GA - Gabon 1
GM - Gambi 1
GP - Guadalupe 1
HT - Haiti 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
ML - Mali 1
MN - Mongolia 1
MW - Malawi 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 3.806
Salva come PNG Salva come JPEG
Città #
San Jose 299
Council Bluffs 240
Singapore 198
Hong Kong 178
Ashburn 118
Los Angeles 87
Columbus 79
Cotonou 59
Moscow 43
Beijing 40
New York 38
Seoul 38
Ho Chi Minh City 36
Santa Clara 36
Lauterbourg 33
Phoenix 31
Buffalo 30
Hanoi 21
Assago 20
St Louis 18
Falkenstein 16
Milan 16
Olathe 16
Dallas 15
Chicago 14
Schaumburg 14
Atlanta 13
Novara 12
Nuremberg 12
Brasília 11
Toronto 11
Chennai 10
Galliate 10
Helsinki 10
Vienna 10
Johannesburg 9
Munich 9
Orem 9
Redondo Beach 9
São Paulo 9
Brooklyn 8
Da Nang 8
Houston 8
Montreal 8
San Francisco 8
Warsaw 8
Naples 7
Rome 7
Shanghai 7
Tokyo 7
Boston 6
Charlotte 6
Denver 6
Frankfurt am Main 6
Guangzhou 6
Tianjin 6
Wheeling 6
Brembate di Sopra 5
Hải Dương 5
Kyiv 5
North Bergen 5
Stockholm 5
Caracas 4
Curitiba 4
Grants Pass 4
Haiphong 4
Kingston 4
Las Vegas 4
Managua 4
Miami 4
Mumbai 4
Newark 4
Tornaco 4
Venice 4
Amsterdam 3
Barcelona 3
Belo Horizonte 3
Buenos Aires 3
Chaguanas 3
Cleveland 3
Hamburg 3
Little River 3
Mexico City 3
Milwaukee 3
Ottawa 3
Parauapebas 3
Phủ Lý 3
Pittsburgh 3
Poplar 3
Rio de Janeiro 3
Riverside 3
San Antonio 3
San Diego 3
Santiago 3
Seattle 3
Turin 3
Willemstad 3
Agrolândia 2
Alajuela 2
Asunción 2
Totale 2.143
Salva come PNG Salva come JPEG
Nome #
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy 135
Frequency and spectrum of PIK3CA somatic mutations in breast cancer 126
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 117
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence 116
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 113
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial 111
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy 110
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies 105
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 100
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 99
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 95
Update on the management of breast cancer during pregnancy 91
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer 91
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 89
Targeted therapies in non–small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management 86
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis 84
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers 80
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 80
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials 80
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 78
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 77
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 77
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 74
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 74
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 71
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 71
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 69
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy 68
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 64
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 64
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer 63
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. 62
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 61
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 59
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 57
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 54
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 53
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 50
Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management 49
Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management 46
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis 46
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 45
Abstract PS2-10-14: Blood-based metabolomic profiling and transcriptomic analysis of circulating cd3+ t cells reveal associations with treatment response and immune activation in early breast cancer (ebc) 44
Luteinizing hormone-releasing hormone analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer 41
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 41
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 41
Management of young women with early breast cancer 41
Management of young women with early breast cancer 41
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis 39
339P Transcriptomic profiling of circulating T lymphocytes predicts response to neoadjuvant therapy in patients with early breast cancer 37
Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer 37
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes 35
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial 35
Abstract PS4-01-16: The transcriptomic profile of circulating T lymphocytes is associated with response to neoadjuvant therapy in patients with early breast cancer 34
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis 28
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study 27
141P Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study 16
null 6
null 5
null 4
null 4
null 2
Totale 3.898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.532
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.532
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025733 0 0 0 87 28 90 63 62 171 82 25 125
2025/20262.221 108 73 151 126 284 117 327 273 217 187 218 140
2026/2027944 169 267 178 330 0 0 0 0 0 0 0 0
Totale 3.898